Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Alastin Skincare, Inc. currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, which means each pending application is being reviewed by a different person at the patent office. The prosecution activity is organized within 3 distinct art units, indicating some technical overlap in the classifications of the 4 pending matters despite the variety of examiners involved.
The busiest examiner for the portfolio is ROSSI, JULIA ANNE LORRAIN, who is currently managing 1 pending office action. Given that there are 4 pending actions and 4 distinct examiners, each examiner is responsible for exactly one matter. This distribution across 3 distinct art units suggests that while the examiners are different, the technical focus remains relatively concentrated within a few specific areas of biotechnology and pharmaceuticals. Practitioners should be prepared to navigate multiple examiner styles across the 3 distinct art units currently handling the 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17981862 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION AND WOUND HEALING | COFFA, SERGIO | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17981862 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION AND WOUND HEALING | COFFA, SERGIO | 14d |
| 18913677 | COMBINATION OF OCTAPEPTIDE AND HIGH MOLECULAR WEIGHT HYALURONIC ACID FOR TOPICAL APPLICATION | ROSSI, JULIA ANNE LORRAIN | — |
| 18179171 | PEPTIDE COMPOSITIONS AND METHODS FOR AMELIORATING SKIN LAXITY AND BODY CONTOUR | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1615 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18913677 | COMBINATION OF OCTAPEPTIDE AND HIGH MOLECULAR WEIGHT HYALURONIC ACID FOR TOPICAL APPLICATION | ROSSI, JULIA ANNE LORRAIN | 1615 | §103DP | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18234795 | COMPOSITIONS AND METHODS RELATING TO ALOPECIA | STEELE, AMBER D | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18179171 | PEPTIDE COMPOSITIONS AND METHODS FOR AMELIORATING SKIN LAXITY AND BODY CONTOUR | BOECKELMAN, JACOB A | 1655 | §103DP | Non-Final OA | — | Pending | Mar 06, 2023 |
| 17981862 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION AND WOUND HEALING | COFFA, SERGIO | 1658 | §103§112 | Final Rejection | 14d | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlastin Skincare, Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Julia Anne Lorrain Rossi has the most, with 1 of Alastin Skincare, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
